Key Highlights
- Eli Lilly launched Lormalzi (donanemab) in India for patients with mild cognitive impairment or mild dementia stages of Alzheimer’s disease following marketing authorization from India’s Central Drugs Standard Control Organization (CDSCO)
- The company priced the 350 mg vial of Lormalzi at ₹91,688 (~$957), with commercial availability expected later this month. The therapy is administered as an intravenous infusion once every four weeks and is designed to remove amyloid plaques associated with Alzheimer’s disease progression
- Donanemab was previously approved in the US under the brand name Kisunla. Eli Lilly and Company has also indicated plans to expand its footprint in India, positioning the country as a growing part of its global manufacturing, export, and commercialization strategy
Implications:
Lormalzi gives Lilly an early foothold in India’s tiny but fast‑growing market for disease‑modifying Alzheimer’s drugs, while it tests how much patients and payers will actually pay for this kind of therapy.
The launch price of about ₹91,700 per 350 mg vial makes each monthly infusion close to a lakh rupees, so near‑term use will likely be limited to wealthy, urban patients and top private hospitals.
Over time, the product helps Lilly build its India presence and could support a broader local manufacturing and export hub strategy, but meaningful volume will depend on future price negotiations, insurance coverage, and whether India scales up diagnostic and infusion capacity for early‑stage Alzheimer’s.
Source: Reuters
No Comment! Be the first one.